Drug intelligence / Profile preview

dacarbazine

Development stage: Approved
Lead developer: Southern Research
Modality: Small Molecules
Administration: Intravenous

Overview

Dacarbazine is a synthetic antineoplastic agent classified as an alkylating agent, primarily used in the treatment of malignant melanoma, Hodgkin lymphoma, and soft tissue sarcoma. It is administered intravenously. Dacarbazine acts mainly by methylating and cross-linking DNA after hepatic activation to its active metabolite (MTIC), thereby inhibiting DNA, RNA, and protein synthesis. It may also function as a purine analog and interact with sulfhydryl groups. The drug was first synthesized at Southern Research in Alabama in 1959 and received FDA approval in 1975. Generic versions are widely available[1][3][4][6][7].

Brand names: DTIC-Dome
Other names: dacarbazineimidazole carboxamide

Targets

DNA

Beyond the preview

Go deeper on dacarbazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dacarbazine.

Explore the full profile